First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.

Authors:
  • SSS. K. Sandhu
    S. K. Sandhu
  • RWR. M. Wenham
    R. M. Wenham
  • GWG. Wilding
    G. Wilding
  • MMM. McFadden
    M. McFadden
  • LSL. Sun
    L. Sun
  • CTC. Toniatti
    C. Toniatti
  • MSM. Stroh
    M. Stroh
  • CCC. L. Carpenter
    C. L. Carpenter
  • JBJ. S. De Bono
    J. S. De Bono
  • WSW. R. Schelman
    W. R. Schelman

Abstract
3001 Background: MK-4827 is a potent, selective, PARP 1/2 inhibitor with IC50 of 3.8nM. MK-4827 induces selective synthetic lethality in homologous recombination (HR) repair deficient tumors with BRCA1/2 loss and tumor cell lines with non-BRCA-related HR defects, supporting clinical utility in sporadic tumors. Methods: MK4827 was administered orally once daily in cohorts of 3-6 pts, enriched for BRCA-deficient and sporadic cancers associated with HR repair defects. Dose escalation was guided by toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) data. Results: 39 pts (male 10, female 29; median age 58 years; 11 BRCA mutation carriers) were treated at 7 successive dose levels [30mg (6), 40mg (3), 60mg (7), 80mg (6), 110mg (5), 150mg (6), 210mg (6)] on days 1-21 of a 28 day cycle (C) in C1, followed by continuous dosing. Overall, dose-limiting toxicity was observed in 3 pts: grade (G) 3 fatigue in 1/6 pts at 30mg, reversible G3 pneumonitis in 1/6 pts at 60mg, and G3 anorexia in 1/6 pts at 210mg. Other M...